Clinical trials: Schizophrenia and Disorders With Psychotic Features
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism
Investigators plan to explore whether Omega-3 fatty acid have effect on the violent behavior of the schizophrenia patients. Investigators will use PET to explore the influence on serotonin function of the brain to understand the…
- Trial name
- NCT02552758
- Testing
- omega-3 fatty acid, positron emission tomography (PET)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Psychotic Disorders
Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
- Trial name
- NCT00255918
- Testing
- Dimethoxybenzylidene anabaseine (DMXB-A)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Schizophrenia and Related Disorders, Bipolar Disorder
Exercise Therapy in Mental Disorders-study
The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder.
- Trial name
- NCT06313918
- Testing
- High intensity training (HIT)
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Haukeland University Hospital
Schizophrenia Disorders
White Matter Plasticity in Schizophrenia
Schizophrenia spectrum disorders are associated with impairment in the microstructure of white matter, the key brain tissue responsible for fast communication between different brain regions necessary for any complex task.
- Trial name
- NCT06641297
- Testing
- Music video game
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Maryland, Baltimore
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Psychotic Disorders
Siltuximab in Schizophrenia
This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Siltuximab (Sylvant) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia.
- Trial name
- NCT02796859
- Testing
- Siltuximab, normal saline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Miller
First Episode Psychosis (FEP)
California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis
The proposed project seeks to create a California early psychosis network using a core assessment battery of valid, low burden measures and mHealth technology platform to collect client-level data, visualize data via clinician…
- Trial name
- EPI-CAL (NCT04007510)
- Testing
- EPI-CAL data network, Community DUP Assessment Tool
- Where
- United States
- Volunteers
- 1,329 people
- Sponsor
- University of California, Davis
Diabetes Mellitus, Type 2, Schizophrenia
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
Schizophrenia is associated with a lifespan shortened by 20 years, due to cardiovascular disease (CVD), with antipsychotic (AP) medications understood to contribute to this risk through associated metabolic side-effects.
- Trial name
- NCT02167620
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
This study will test the safety of an aripiprazole injection in subjects with schizophrenia that are currently taking oral antipsychotic medication other than aripiprazole.
- Trial name
- NCT01552772
- Testing
- Aripiprazole IM Depot
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophreniform Disorders
Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment
In this study we, the investigators at UMC Utrecht, intend to investigate changes in brain activation patterns using functional magnetic resonance imaging (MRI), in patients suffering from schizophrenia who are medication naive…
- Trial name
- NCT00161057
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Schizophrenia, Psychotic Disorders
Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
The purpose of this research study is to see how well patients in an early phase of their illness respond to treatment and whether this depends on how well they functioned socially, academically and vocationally before becoming…
- Conditions
- Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
- Trial name
- NCT00369239
- Testing
- risperidone long acting injectable
- Volunteers
- 303 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia and Related Disorders
Clay Therapy in Schizophrenia Patients
In recent years, art therapies have been discussed for their positive effects on mental disorders. One such therapy, clay therapy, is being studied to examine its effect on the functional recovery and individual and social…
- Trial name
- NCT07378150
- Testing
- Clay therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people
- Sponsor
- Kutahya Health Sciences University
Psychosis
CLinical Utility of Early Intervention Including the 5-Step Precision Medicine (5SPM) Method in First-episode Psychosis: The CLUMP Project
CLUMP is a project of translational research that intends to bridge the gap between what we already know about pharmacogenetics of antipsychotic drugs and what we still do to treat patients with first-episode psychosis (FEP).
- Trial name
- CLUMP (NCT06453174)
- Testing
- Adherence to the first prescribed antipsychotic medication
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Auditory Hallucinations in Patients With Schizophrenic Disorders
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study
Background: Repetitive transcranial magnetic stimulation (rTMS) is a recent therapeutic which has demonstrated its efficacy in the treatment of auditory hallucinations in patients with schizophrenic disorders.
- Trial name
- TMS-Hz (NCT01022489)
- Testing
- Transcranial magnetic stimulation: rTMS
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Caen
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects
This study is being conducted to assess the safety and tolerability of ascending multiple oral doses of SCA-136 administered to healthy Japanese male subjects.
- Trial name
- NCT00505973
- Testing
- SCA-136
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Schizophrenia
Measurement of Activity Participation for Persons With Schizophrenia Living in the Community
The purpose of the study is to develop a questionnaire on community occupational participation for persons with schizophrenia living in the community.
- Trial name
- NCT00172731
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.